RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and lowers the price target from $431 to $425.
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.